The Share

[{"d":"2024-01-22","n":"Curasight A/S Achieves First Milestone under collaboration with Curium Inc.","u":"/news/press-releases/2024/curasight-as-achieves-first-milestone-under-collaboration-with-curium-inc/"},{"d":"2024-02-13","n":"Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company","u":"/news/press-releases/2024/curasight-announces-acceleration-of-therapeutic-strategy-to-strengthen-position-as-a-radiopharmaceutical-theranostic-company/"},{"d":"2024-02-13","n":"Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy","u":"/investor/rights-issue-2024/curasight-resolves-on-a-rights-issue-of-up-to-dkk-51-2-million-to-accelerate-its-therapeutic-strategy/"},{"d":"2024-02-22","n":"Year-end report October – December 2023","u":"/news/press-releases/2024/year-end-report-october-december-2023/"},{"d":"2024-02-22","n":"Annual Report for the fiscal year 2023","u":"/news/press-releases/2024/annual-report-for-the-fiscal-year-2023/"},{"d":"2024-02-22","n":"Curasight publishes information memorandum in connection with forthcoming rights issue","u":"/investor/rights-issue-2024/curasight-publishes-information-memorandum-in-connection-with-forthcoming-rights-issue/"},{"d":"2024-02-23","n":"The subscription period in Curasight’s rights issue begins today","u":"/investor/rights-issue-2024/the-subscription-period-in-curasights-rights-issue-begins-today/"},{"d":"2024-03-06","n":"Notice of Annual General Meeting 2024","u":"/news/press-releases/2024/notice-of-annual-general-meeting-2024/"},{"d":"2024-03-11","n":"Curasight not to proceed with rights issue; evaluating alternative financing opportunities","u":"/news/press-releases/2024/curasight-not-to-proceed-with-rights-issue-evaluating-alternative-financing-opportunities/"},{"d":"2024-03-21","n":"Resolutions of the Annual General Meeting 2024 of Curasight A/S","u":"/news/press-releases/2024/resolutions-of-the-annual-general-meeting-2024-of-curasight-as/"},{"d":"2024-04-12","n":"Curasight announces change in the Board of Directors","u":"/news/press-releases/2024/curasight-announces-change-in-the-board-of-directors/"},{"d":"2024-04-16","n":"Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients","u":"/news/press-releases/2024/curasight-announces-approval-of-clinical-trial-application-cta-for-phase-2-trial-with-utrace-in-prostate-cancer-patients/"},{"d":"2024-05-23","n":"Interim report Q1 2024","u":"/news/press-releases/2024/interim-report-q1-2024/"},{"d":"2024-06-12","n":"Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer","u":"/news/press-releases/2024/curasight-announces-enrollment-of-first-patient-in-phase-2-trial-with-utrace-in-prostate-cancer/"},{"d":"2024-06-14","n":"Curasight A/S resolves on directed issues and a loan facility","u":"/news/press-releases/2024/curasight-as-resolves-on-directed-issues-and-a-loan-facility/"},{"d":"2024-06-17","n":"Notice of Extraordinary General Meeting","u":"/news/press-releases/2024/notice-of-extraordinary-general-meeting/"},{"d":"2024-06-22","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2024/curasight-to-present-at-hc-andersen-capital/"},{"d":"2024-07-01","n":"Directed issues registered at the Danish Business Authority","u":"/news/press-releases/2024/directed-issues-registered-at-the-danish-business-authority/"},{"d":"2024-07-02","n":"Resolutions of the Extraordinary General Meeting of Curasight A/S on 2 July 2024","u":"/news/press-releases/2024/resolutions-of-the-extraordinary-general-meeting-of-curasight-as-on-2-july-2024/"},{"d":"2024-07-30","n":"Curasight issues warrants as part of long-term incentive program","u":"/news/press-releases/2024/curasight-issues-warrants-as-part-of-long-term-incentive-program/"},{"d":"2024-08-22","n":"Interim report Q2 2024","u":"/news/press-releases/2024/interim-report-q2-2024/"},{"d":"2024-09-04","n":"The Board of Directors resolves on a directed issue of units and preferential rights issue of units","u":"/news/press-releases/2024/the-board-of-directors-resolves-on-a-directed-issue-of-units-and-preferential-rights-issue-of-units/"},{"d":"2024-09-12","n":"Curasight A/S publishes prospectus due to upcoming rights issue","u":"/news/press-releases/2024/curasight-as-publishes-prospectus-due-to-upcoming-rights-issue/"},{"d":"2024-09-16","n":"Commencement of subscription period in Curasight’s preferential rights issue","u":"/news/press-releases/2024/commencement-of-subscription-period-in-curasights-preferential-rights-issue/"},{"d":"2024-10-03","n":"Curasight A/S rights issue heavily oversubscribed","u":"/news/press-releases/2024/curasight-as-rights-issue-heavily-oversubscribed/"},{"d":"2024-10-11","n":"Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3","u":"/news/press-releases/2024/curasight-as-announces-last-day-of-trading-in-btu-and-first-day-of-trading-in-warrant-series-to2-and-to3/"},{"d":"2024-11-07","n":"Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer","u":"/news/press-releases/2024/clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients-published-data-supports-development-of-utreat-for-brain-cancer/"},{"d":"2024-11-08","n":"Curasight to present at Dansk Aktionærforening InvestorDagen","u":"/news/press-releases/2024/curasight-to-present-at-dansk-aktionaerforening-investordagen/"},{"d":"2024-11-11","n":"Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025","u":"/news/press-releases/2024/curasight-announces-brain-cancer-as-first-indication-for-utreat-first-patient-to-be-dosed-q2-2025/"},{"d":"2024-11-13","n":"Curasight announces international patent application for uTREAT® to broaden IP protection","u":"/news/press-releases/2024/curasight-announces-international-patent-application-for-utreat-to-broaden-ip-protection/"},{"d":"2024-11-14","n":"Curasight to present at HC Andersen Capital, BioStock Life Science Summit 2024, and Økonomisk Ugebrev Investor Conference","u":"/news/press-releases/2024/curasight-to-present-at-hc-andersen-capital-biostock-life-science-summit-2024-and-okonomisk-ugebrev-investor-conference/"},{"d":"2024-11-20","n":"The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share","u":"/news/press-releases/2024/the-exercise-price-for-warrants-of-series-to2-has-been-set-to-dkk-11-50-per-new-share/"},{"d":"2024-11-21","n":"Interim report Q3 2024","u":"/news/press-releases/2024/interim-report-q3-2024/"},{"d":"2024-11-21","n":"The exercise period for warrants of series TO2 commences today","u":"/news/press-releases/2024/the-exercise-period-for-warrants-of-series-to2-commences-today/"},{"d":"2024-11-22","n":"Curasight and Curium sign global radioisotope supply agreement for uTREAT[®]","u":"/news/press-releases/2024/curasight-and-curium-sign-global-radioisotope-supply-agreement-for-utreat/"},{"d":"2024-12-02","n":"The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024","u":"/news/press-releases/2024/the-last-day-of-trading-in-warrants-of-series-to2-is-on-the-3rd-of-december-2024/"},{"d":"2024-12-02","n":"SEB maintain valuation range midpoint at DKK 54 per share","u":"/news/press-releases/2024/seb-maintain-valuation-range-midpoint-at-dkk-54-per-share/"},{"d":"2024-12-10","n":"Curasight A/S announces outcome of warrant exercise","u":"/news/press-releases/2024/curasight-as-announces-outcome-of-warrant-exercise/"},{"d":"2024-12-10","n":"Participation in warrant exercise by Curasight management","u":"/news/press-releases/2024/participation-in-warrant-exercise-by-curasight-management/"},{"d":"2023-01-16","n":"Curasight to present at Redeye Fight Cancer Seminar","u":"/news/press-releases/2023/curasight-to-present-at-redeye-fight-cancer-seminar/"},{"d":"2023-02-22","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital/"},{"d":"2023-02-23","n":"Year-end report October - December 2022","u":"/news/press-releases/2023/year-end-report-october---december-2022/"},{"d":"2023-02-23","n":"Annual Report for the fiscal year 2022","u":"/news/press-releases/2023/annual-report-for-the-fiscal-year-2022/"},{"d":"2023-03-15","n":"Notice of Annual General Meeting 2023","u":"/news/press-releases/2023/notice-of-annual-general-meeting-2023/"},{"d":"2023-03-30","n":"Resolutions of the Annual General Meeting of Curasight A/S","u":"/news/press-releases/2023/resolutions-of-the-annual-general-meeting-of-curasight-as/"},{"d":"2023-05-01","n":"Curasight and Curium announce global partnership for uTRACE[®] in prostate cancer","u":"/news/press-releases/2023/curasight-and-curium-announce-global-partnership-for-utrace-in-prostate-cancer/"},{"d":"2023-05-25","n":"Interim report Q1 2023","u":"/news/press-releases/2023/interim-report-q1-2023/"},{"d":"2023-05-26","n":"Curasight to present at HC Andersen Capital and Økonomisk Ugebrev","u":"/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital-and-okonomisk-ugebrev/"},{"d":"2023-06-07","n":"Curasight A/S reports positive preclinical results with uTREAT[®] in aggressive brain cancer (glioblastoma)","u":"/news/press-releases/2023/curasight-as-reports-positive-preclinical-results-with-utreat-in-aggressive-brain-cancer-glioblastoma/"},{"d":"2023-06-29","n":"Positive results in uPAR-PET/MR Phase II study in brain cancer","u":"/news/press-releases/2023/positive-results-in-upar-petmr-phase-ii-study-in-brain-cancer/"},{"d":"2023-08-24","n":"Interim Report January – June 2023","u":"/news/press-releases/2023/interim-report-january--june-2023/"},{"d":"2023-08-25","n":"Curasight to present at HC Andersen Capital and at HC Andersen Life Science seminar","u":"/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital-and-at-hc-andersen-life-science-seminar/"},{"d":"2023-09-14","n":"Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague","u":"/news/press-releases/2023/positive-results-from-the-phase-ii-study-of-utrace-in-brain-cancer-presented-at-the-world-molecular-imaging-congress-wmic-2023-in-prague/"},{"d":"2023-10-18","n":"Curasight A/S reports positive preclinical results with uTREAT[®] in lung cancer (NSCLC)","u":"/news/press-releases/2023/curasight-as-reports-positive-preclinical-results-with-utreat-in-lung-cancer-nsclc/"},{"d":"2023-11-23","n":"Interim Report January – September 2023","u":"/news/press-releases/2023/interim-report-january--september-2023/"},{"d":"2023-11-24","n":"Curasight to present at HC Andersen Capital and Stokk.io","u":"/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital-and-stokkio/"},{"d":"2023-12-13","n":"Curasight A/S appoints CRO to run Phase 2 study with uTRACE[®] in prostate cancer","u":"/news/press-releases/2023/curasight-as-appoints-cro-to-run-phase-2-study-with-utrace-in-prostate-cancer/"},{"d":"2023-12-18","n":"Curasight A/S submits clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients","u":"/news/press-releases/2023/curasight-as-submits-clinical-trial-application-cta-for-phase-2-trial-with-utrace-in-prostate-cancer-patients/"},{"d":"2022-01-18","n":"Curasight presents at the SEB Nordic Healthcare Seminar 2022 and at Kapital Partner","u":"/news/press-releases/2022/curasight-presents-at-the-seb-nordic-healthcare-seminar-2022-and-at-kapital-partner/"},{"d":"2022-01-27","n":"Phase II study of uPAR-PET in neuroendocrine tumor patients demonstrates strong prognostic value and supports potential future use of uPAR-targeted radionuclide therapy","u":"/news/press-releases/2022/phase-ii-study-of-upar-pet-in-neuroendocrine-tumor-patients-demonstrates-strong-prognostic-value-and-supports-potential-future-use-of-upar-targeted-radionuclide-therapy/"},{"d":"2022-02-10","n":"Curasight strengthens its strategic position with the acquisition of TRT Innovations ApS","u":"/news/press-releases/2022/curasight-strengthens-its-strategic-position-with-the-acquisition-of-trt-innovations-aps/"},{"d":"2022-02-23","n":"Curasight expands its strategy and strengthen its position as a theranostic company","u":"/news/press-releases/2022/curasight-expands-its-strategy-and-strengthen-its-position-as-a-theranostic-company/"},{"d":"2022-02-24","n":"Year-end report October - December 2021","u":"/news/press-releases/2022/year-end-report-october---december-2021/"},{"d":"2022-02-24","n":"Annual Report for the fiscal year 2021","u":"/news/press-releases/2022/annual-report-for-the-fiscal-year-2021/"},{"d":"2022-03-09","n":"Curasight announces new date of the Annual General Meeting and an updated financial calendar 2022","u":"/news/press-releases/2022/curasight-announces-new-date-of-the-annual-general-meeting-and-an-updated-financial-calendar-2022/"},{"d":"2022-04-12","n":"Notice of Annual General Meeting 2022","u":"/news/press-releases/2022/notice-of-annual-general-meeting-2022/"},{"d":"2022-04-22","n":"Additional US patent application relating to uTRACE[®] is accepted for grant","u":"/news/press-releases/2022/additional-us-patent-application-relating-to-utrace-is-accepted-for-grant/"},{"d":"2022-04-27","n":"Resolutions of the Annual General Meeting of Curasight A/S","u":"/news/press-releases/2022/resolutions-of-the-annual-general-meeting-of-curasight-as/"},{"d":"2022-05-16","n":"Curasight to present at Kapital Partners Life Science seminar","u":"/news/press-releases/2022/curasight-to-present-at-kapital-partners-life-science-seminar/"},{"d":"2022-05-24","n":"Interim Report January - March 2022","u":"/news/press-releases/2022/interim-report-january---march-2022/"},{"d":"2022-06-07","n":"Curasight issues warrants for launch of long-term incentive program","u":"/news/press-releases/2022/curasight-issues-warrants-for-launch-of-long-term-incentive-program/"},{"d":"2022-06-24","n":"Transaction with shares in Curasight A/S made by managerial employee","u":"/news/press-releases/2022/transaction-with-shares-in-curasight-as-made-by-managerial-employee/"},{"d":"2022-06-30","n":"Recruitment completed in uPAR-PET study in brain cancer","u":"/news/press-releases/2022/recruitment-completed-in-upar-pet-study-in-brain-cancer/"},{"d":"2022-08-25","n":"Interim Report January – June 2022","u":"/news/press-releases/2022/interim-report-january--june-2022/"},{"d":"2022-08-25","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2022/curasight-to-present-at-hc-andersen-capital/"},{"d":"2022-09-04","n":"Transaction with shares in Curasight A/S made by managerial employee","u":"/news/press-releases/2022/transaction-with-shares-in-curasight-as-made-by-managerial-employee-2022-09-04/"},{"d":"2022-10-13","n":"Curasight initiates pre-clinical studies with uTREAT[®] therapy in head and neck cancer (HNSCC) and neuroendocrine tumors (NET)","u":"/news/press-releases/2022/curasight-initiates-pre-clinical-studies-with-utreat-therapy-in-head-and-neck-cancer-hnscc-and-neuroendocrine-tumors-net/"},{"d":"2022-11-17","n":"Curasight to present at SEB Healthcare Seminar 2022","u":"/news/press-releases/2022/curasight-to-present-at-seb-healthcare-seminar-2022/"},{"d":"2022-11-23","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2022/curasight-to-present-at-hc-andersen-capital-2022-11-23/"},{"d":"2022-11-24","n":"Interim Report January – September 2022","u":"/news/press-releases/2022/interim-report-january--september-2022/"},{"d":"2021-09-01","n":"Curasight A/S strengthens its institutional investor base","u":"/news/press-releases/2021/curasight-as-strengthens-its-institutional-investor-base/"},{"d":"2021-09-16","n":"The exercise period for warrants of series TO 1 in Curasight A/S begins today","u":"/news/press-releases/2021/the-exercise-period-for-warrants-of-series-to-1-in-curasight-as-begins-today/"},{"d":"2021-09-21","n":"Transactions with warrants of series TO 1 in Curasight A/S made by managerial employees and their closely associated persons","u":"/news/press-releases/2021/transactions-with-warrants-of-series-to-1-in-curasight-as-made-by-managerial-employees-and-their-closely-associated-persons/"},{"d":"2021-09-30","n":"Curasight warrant TO 1 – last day of trading is Tuesday 5 October 2021","u":"/news/press-releases/2021/curasight-warrant-to-1--last-day-of-trading-is-tuesday-5-october-2021/"},{"d":"2021-10-11","n":"Curasight A/S receives approximately DKK 47.6 million through exercise of warrants of series TO 1","u":"/news/press-releases/2021/curasight-as-receives-approximately-dkk-476-million-through-exercise-of-warrants-of-series-to-1/"},{"d":"2021-10-13","n":"Curasight A/S warrant exercise registered at Erhvervsstyrelsen","u":"/news/press-releases/2021/curasight-as-warrant-exercise-registered-at-erhvervsstyrelsen/"},{"d":"2021-10-15","n":"Curasight A/S presents at BioStock Life Science Summit 20 October 2021","u":"/news/press-releases/2021/curasight-as-presents-at-biostock-life-science-summit-20-october-2021/"},{"d":"2021-10-15","n":"Curasight A/S presents at Økonomisk Ugebrev Life Science Investor Conference in Copenhagen 20 October 2021","u":"/news/press-releases/2021/curasight-as-presents-at-okonomisk-ugebrev-life-science-investor-conference-in-copenhagen-20-october-2021/"},{"d":"2021-11-23","n":"Curasight presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-presents-at-hc-andersen-capital-2021-11-23/"},{"d":"2021-11-25","n":"Interim report January – September 2021","u":"/news/press-releases/2021/interim-report-january--september-2021/"},{"d":"2021-12-06","n":"Curasight A/S presents at Sedermeradagen in Copenhagen 7 December 2021","u":"/news/press-releases/2021/curasight-as-presents-at-sedermeradagen-in-copenhagen-7-december-2021/"},{"d":"2021-12-07","n":"Curasight A/S presents at HC Andersen Capital & Nordea Markets Virtual Growth Days seminar - 9 December 2021","u":"/news/press-releases/2021/curasight-as-presents-at-hc-andersen-capital--nordea-markets-virtual-growth-days-seminar---9-december-2021/"},{"d":"2021-12-09","n":"Phase II study demonstrates prognostic value of uPAR-PET in head and neck cancer patients","u":"/news/press-releases/2021/phase-ii-study-demonstrates-prognostic-value-of-upar-pet-in-head-and-neck-cancer-patients/"},{"d":"2021-12-13","n":"Curasight presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-presents-at-hc-andersen-capital-2021-12-13/"},{"d":"2021-12-14","n":"Transaction with shares in Curasight A/S made by managerial employee","u":"/news/press-releases/2021/transaction-with-shares-in-curasight-as-made-by-managerial-employee/"},{"d":"2021-12-21","n":"Hanne Damgaard Jensen joins Curasight A/S as Chief Development Officer (CDO)","u":"/news/press-releases/2021/hanne-damgaard-jensen-joins-curasight-as-as-chief-development-officer-cdo/"},{"d":"2021-12-30","n":"Curasight attends the J.P. Morgan Healthcare Conference and presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-attends-the-jp-morgan-healthcare-conference-and-presents-at-hc-andersen-capital/"},{"d":"2021-08-24","n":"Interim report January – June 2021","u":"/news/press-releases/2021/interim-report-january--june-2021/"},{"d":"2021-08-23","n":"Curasight presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-presents-at-hc-andersen-capital/"},{"d":"2021-02-08","n":"US patent application 14/399,820 relating to uTREAT[®] is accepted for grant","u":"/news/press-releases/2021/us-patent-application-14399820-relating-to-utreat-is-accepted-for-grant/"},{"d":"2021-02-24","n":"Year-end report October – December 2020","u":"/news/press-releases/2021/year-end-report-october--december-2020/"},{"d":"2021-02-24","n":"Annual Report for the fiscal year 2020","u":"/news/press-releases/2021/annual-report-for-the-fiscal-year-2020/"},{"d":"2021-02-26","n":"Article from Phase II study in prostate cancer now published in the March issue of Journal of Nuclear Medicine and highlighted as best clinical investigation article","u":"/news/press-releases/2021/article-from-phase-ii-study-in-prostate-cancer-now-published-in-the-march-issue-of-journal-of-nuclear-medicine-and-highlighted-as-best-clinical-investigation-article/"},{"d":"2021-03-05","n":"Curasight A/S presents at Økonomisk Ugebrev Life Science Investor Conference","u":"/news/press-releases/2021/curasight-as-presents-at-okonomisk-ugebrev-life-science-investor-conference/"},{"d":"2021-03-11","n":"Notice of Annual General Meeting","u":"/news/press-releases/2021/notice-of-annual-general-meeting/"},{"d":"2021-03-11","n":"Curasight’s presentation at Økonomisk Ugebrev Life Science Investor Conference is now available","u":"/news/press-releases/2021/curasights-presentation-at-okonomisk-ugebrev-life-science-investor-conference-is-now-available/"},{"d":"2021-03-25","n":"Minutes from the Annual General Meeting in Curasight A/S","u":"/news/press-releases/2021/minutes-from-the-annual-general-meeting-in-curasight-as/"},{"d":"2021-03-28","n":"CAD patent application 2,905,172 relating to uTREAT[®] is accepted for grant","u":"/news/press-releases/2021/cad-patent-application-2905172-relating-to-utreat-is-accepted-for-grant/"},{"d":"2021-04-09","n":"Curasight A/S presents at Nordnet Live - Spotlight Small Cap investor conference 15 April 2021","u":"/news/press-releases/2021/curasight-as-presents-at-nordnet-live---spotlight-small-cap-investor-conference-15-april-2021/"},{"d":"2021-05-04","n":"Curasight announces appointment of Dr. Kirsten Drejer as new board member","u":"/news/press-releases/2021/curasight-announces-appointment-of-dr-kirsten-drejer-as-new-board-member/"},{"d":"2021-05-17","n":"Curasight is awarded two prizes in Best IPO 2020 by the independent IPO Guide","u":"/news/press-releases/2021/curasight-is-awarded-two-prizes-in-best-ipo-2020-by-the-independent-ipo-guide/"},{"d":"2021-05-18","n":"Notice of Extraordinary General Meeting","u":"/news/press-releases/2021/notice-of-extraordinary-general-meeting/"},{"d":"2021-05-20","n":"Interim report January – March 2021","u":"/news/press-releases/2021/interim-report-january--march-2021/"},{"d":"2021-05-20","n":"Interim report January – March 2021 – Correction","u":"/news/press-releases/2021/interim-report-january--march-2021--correction/"},{"d":"2021-05-21","n":"Curasight presents at Erik Penser Bank – Temadag Medicinsk Bildteknik & Diagnostik","u":"/news/press-releases/2021/curasight-presents-at-erik-penser-bank--temadag-medicinsk-bildteknik--diagnostik/"},{"d":"2021-05-26","n":"Curasight presents at Bio Stock Life Science Spring Summit","u":"/news/press-releases/2021/curasight-presents-at-bio-stock-life-science-spring-summit/"},{"d":"2021-06-01","n":"Minutes from the Extraordinary General Meeting in Curasight A/S","u":"/news/press-releases/2021/minutes-from-the-extraordinary-general-meeting-in-curasight-as/"},{"d":"2021-06-18","n":"SEB initiates commissioned research on Curasight A/S","u":"/news/press-releases/2021/seb-initiates-commissioned-research-on-curasight-as/"},{"d":"2021-06-24","n":"Positive data of uTREAT® in glioblastoma provides “green light” to proceed with next steps","u":"/news/press-releases/2021/positive-data-of-utreat-in-glioblastoma-provides-green-light-to-proceed-with-next-steps/"},{"d":"2020-09-03","n":"The subscription period in Curasight’s issue of units starts today","u":"/news/press-releases/2020/the-subscription-period-in-curasights-issue-of-units-starts-today/"},{"d":"2020-09-02","n":"Curasight A/S receives approval for listing and publishes prospectus","u":"/news/press-releases/2020/curasight-as-receives-approval-for-listing-and-publishes-prospectus/"},{"d":"2020-09-09","n":"Webcast with Curasight","u":"/news/press-releases/2020/webcast-with-curasight/"},{"d":"2020-09-22","n":"Significantly oversubscribed IPO of units in Curasight","u":"/news/press-releases/2020/significantly-oversubscribed-ipo-of-units-in-curasight/"},{"d":"2020-10-08","n":"First day of trading in Curasight’s shares and warrants at Spotlight Stock Market","u":"/news/press-releases/2020/first-day-of-trading-in-curasights-shares-and-warrants-at-spotlight-stock-market/"},{"d":"2020-10-07","n":"Prolongation and expansion of agreement with TRT Innovations ApS","u":"/news/press-releases/2020/prolongation-and-expansion-of-agreement-with-trt-innovations-aps/"},{"d":"2020-10-22","n":"Canadian patent application relating to uTRACE[®] is ready for allowance in Canada","u":"/news/press-releases/2020/canadian-patent-application-relating-to-utrace-is-ready-for-allowance-in-canada/"},{"d":"2020-11-11","n":"Curasight initiates pre-clinical study on therapy (uTREAT[®]) in brain cancer and signs CRO-agreement","u":"/news/press-releases/2020/curasight-initiates-pre-clinical-study-on-therapy-utreat-in-brain-cancer-and-signs-cro-agreement/"},{"d":"2020-11-30","n":"Interim report January – September 2020","u":"/news/press-releases/2020/interim-report-january--september-2020/"},{"d":"2020-12-15","n":"Financial Calendar 2021","u":"/news/press-releases/2020/financial-calendar-2021/"},{"d":"2020-12-16","n":"Japanese patent application 2019-005811 is accepted for grant","u":"/news/press-releases/2020/japanese-patent-application-2019-005811-is-accepted-for-grant/"},{"d":"2020-12-21","n":"Results from Phase II study in prostate cancer to be published in the Journal of Nuclear Medicine","u":"/news/press-releases/2020/results-from-phase-ii-study-in-prostate-cancer-to-be-published-in-the-journal-of-nuclear-medicine/"},{"d":"2024-02-13","n":"Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy","u":"/investor/rights-issue-2024/curasight-resolves-on-a-rights-issue-of-up-to-dkk-51-2-million-to-accelerate-its-therapeutic-strategy/"},{"d":"2024-02-22","n":"Curasight publishes information memorandum in connection with forthcoming rights issue","u":"/investor/rights-issue-2024/curasight-publishes-information-memorandum-in-connection-with-forthcoming-rights-issue/"},{"d":"2024-02-23","n":"The subscription period in Curasight’s rights issue begins today","u":"/investor/rights-issue-2024/the-subscription-period-in-curasights-rights-issue-begins-today/"}]